Company Overview of MiddleBrook Pharmaceuticals, Inc.
As of January 3, 2011, MiddleBrook Pharmaceuticals, Inc. went out of business. MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products using its proprietary delivery technology, PULSYS in the United States. Its product portfolio includes MOXATAG tablets for the treatment of pharyngitis and tonsillitis; and KEFLEX capsules for the treatment of skin and skin structure infections, and upper respiratory tract infections. It sells its products directly to wholesalers, and food and drug chains. The company was formerly known as Advancis Pharmaceutical Corporation and changed its name to MiddleBrook Pharmaceutical...
7 Village Circle
Westlake, TX 76262
Founded in 1999
Key Executives for MiddleBrook Pharmaceuticals, Inc.
MiddleBrook Pharmaceuticals, Inc. does not have any Key Executives recorded.
MiddleBrook Pharmaceuticals, Inc. Key Developments
SEC Revokes Registration Of Registered Securities Of MiddleBrook Pharmaceuticals, Inc
Jul 29 14
An Administrative Law Judge has issued an Initial Decision of Default as to MiddleBrook Pharmaceuticals, Inc. The Initial Decision found that the company was issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and the company failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by not filing required periodic reports with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of the company’s registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.
SEC Orders Hearings On Registration Suspension Or Revocation Against MiddleBrook Pharmaceuticals, Inc. For Failure To Make Required Periodic Filings
Jun 25 14
Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of MiddleBrook Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries